Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

Strasbourg, France, August 19, 2015 – Transgene S.A. (Euronext: TNG) today announced that results, including more mature overall survival data, from the Phase 2b part of the Phase 2b/3 TIME trial with its immunotherapy candidate TG4010 in non-small cell lung cancer, will be presented at the 16th World Conference on Lung Cancer to be held in Denver, Colorado, USA, September 6-9, 2015. The conference is being hosted by the International Association for the Study of Lung Cancer (IASLC).

The presentation, TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results, will be given by Elisabeth Quoix, M.D., Ph.D., Head of the Department of Pulmonology at the University Hospital of Strasbourg and Coordinating Investigator of the TIME study, on Tuesday, September 8, 2015. The presentation will be part of Oral Session 18: Non PD1 Immunotherapy and Angiogenesis, which is part of the Treatment of Advanced Diseases – NSCLC track.

Abstracts will be available online on the IASLC website beginning on August 21, 2015 at 4 PM Pacific Time.

About TG4010

TG4010, a novel MUC1 targeted immunotherapy, is being developed for the treatment of metastatic non-small cell lung cancer. TG4010 is a recombinant vaccinia virus of the Ankara strain (MVA) expressing the coding sequences of the MUC1 antigen and of the cytokine, Interleukin-2 (IL2). In healthy cells, the MUC1 protein is normally found on the surface of epithelial cells in many types of tissue and works to protect these cells. In tumor cells, several modifications of MUC1 can occur: over expression, hypo-glycosylation and changes in cellular localization. These changes transform the MUC1 protein into a highly immunogenic tumor associated antigen (TAA) and make it an attractive target for cancer immunotherapy. Thus, the strategy is to induce MUC1 antigen expression in a non-tumor environment, i.e., where the immune system is fully functional, in order to induce both innate and MUC1 specific adaptive immunity. In addition to NSCLC, the MUC1 TAA is expressed in many other solid tumor types, such as lung, breast, colorectal, kidney and prostate cancers.

About Transgene

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.

Contacts:

Transgene
Elisabetta Castelli, Director Investor Relations
+33 (0)3 88 27 91 21

Laurie Doyle, Director Investor Relations US & Corporate Communications
+1 (339) 832 0752

investorrelations@transgene.fr

MC Services
Raimund Gabriel
+49 089 210 228 30
raimund.gabriel@mc-services.eu

Shaun Brown
+44 207 148 5998
shaun.brown@mc-services.eu